Literature DB >> 27484158

Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.

Emmanuel Belchior1, Daniel Lévy-Bruhl1, Yann Le Strat1, Magid Herida1.   

Abstract

A vaccine against herpes zoster (HZ) and its complications has already proven safe and effective against infection and pain and against the related deterioration of quality of life in the elderly. In order to inform the vaccination decision-making process regarding inclusion of this vaccine in the French immunization schedule, we assessed the cost-effectiveness of several vaccination scenarios, compared to no vaccination. We chose to use a previously published Markov model. Starting vaccination in elderly individuals aged 65, 70 and 75 y old appears more cost-effective than vaccination for those aged 60 y old, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the first 3 age groups versus 54,500 €; for the latter group. These results largely contributed to the recommendation to include the HZ vaccination in the French immunization schedule for people aged between 65 and 74 y old in France.

Entities:  

Keywords:  Herpes zoster; cost-effectiveness; epidemiology; infectious disease; mathematical modeling; postherpetic neuralgia; vaccination; vaccine; vaccinology; viral

Mesh：

Substances：

Year:  2016        PMID： 27484158      PMCID： PMC5027734          DOI： 10.1080/21645515.2016.1184801

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  13 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  Herpes zoster: Burden of disease in France.

Authors:  S Gonzalez Chiappe; M Sarazin; C Turbelin; A Lasserre; C Pelat; I Bonmarin; O Chosidow; T Blanchon; T Hanslik
Journal:  Vaccine       Date:  2010-10-12       Impact factor: 3.641

3.  [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over].

Authors:  G Mick; J-L Gallais; F Simon; S Pinchinat; K Bloch; M Beillat; L Serradell; T Derrough
Journal:  Rev Epidemiol Sante Publique       Date:  2010-11-20       Impact factor: 1.019

4.  Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

Authors:  A J van Hoek; N Gay; A Melegaro; W Opstelten; W J Edmunds
Journal:  Vaccine       Date:  2009-01-09       Impact factor: 3.641

5.  Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Authors:  Xavier Bresse; Lieven Annemans; Emmanuelle Préaud; Karine Bloch; Gérard Duru; Aline Gauthier
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2013-03-28       Impact factor: 2.217

Review 6.  Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.

Authors:  Kosuke Kawai; Emmanuelle Preaud; Florence Baron-Papillon; Nathalie Largeron; Camilo J Acosta
Journal:  Vaccine       Date:  2014-02-15       Impact factor: 3.641

7.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

8.  Postherpetic neuralgia.

Authors:  R E Hope-Simpson
Journal:  J R Coll Gen Pract       Date:  1975-08

9.  Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.

Authors:  Cecile Blein; Gaetan Gavazzi; Marc Paccalin; Charles Baptiste; Gilles Berrut; Alexandre Vainchtock
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

Review 10.  Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Authors:  Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann
Journal:  BMC Public Health       Date:  2015-06-05       Impact factor: 3.295
View more
  5 in total

1.  Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Authors:  Xiaoqing Cheng; Yueyuan Zhao; Xuefeng Zhang; Hui Jin; Jie Min
Journal:  Hum Vaccin Immunother       Date:  2017-04-27       Impact factor: 3.452

2.  Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.

Authors:  Edward T Chiyaka; Van T Nghiem; Lu Zhang; Abhishek Deshpande; Patricia Dolan Mullen; Phuc Le
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.558

3.  Herpes zoster vaccine: A health economic evaluation for Switzerland.

Authors:  Patricia R Blank; Zanfina Ademi; Xiaoyan Lu; Thomas D Szucs; Matthias Schwenkglenks
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

4.  Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.

Authors:  Ellen Wolff; Katarina Widgren; Gianpaolo Scalia Tomba; Adam Roth; Tiia Lep; Sören Andersson
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

Review 5.  Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.

Authors:  Catherina X Pan; Michelle S Lee; Vinod E Nambudiri
Journal:  Ther Adv Vaccines Immunother       Date:  2022-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.